Buy Rating Affirmed: TScan Therapeutics’ Innovative TCR-T Therapy and Strategic Milestones Promising for 2024

H.C. Wainwright analyst Andrew Fein reiterated a Buy rating on TScan Therapeutics (TCRX – Research Report) today and set a price target of $15.00.

Andrew Fein has given his Buy rating due to a combination of factors surrounding TScan Therapeutics’ innovative approach to treating both solid and liquid tumors. Fein is particularly optimistic about the promise of TScan’s TCR-T therapy, which targets cancer-associated antigens with high precision. The company’s proprietary platform, dubbed Target/ReceptorScan, is instrumental in identifying highly active, naturally occurring TCRs that combat cancer-specific targets. This technology underpins TScan’s ImmunoBank, a growing collection of TCR-T candidates poised for clinical trials. Fein’s confidence is bolstered by TScan’s strategic multi-target treatment approach, which is anticipated to enhance patient response rates and the durability of those responses.

Fein’s positive outlook is further reinforced by TScan’s robust development pipeline and the anticipated milestones throughout 2024. Key catalysts include the expansion of Phase 2 dose-level cohorts for TScan’s hematology malignancy programs, as well as the reporting of comprehensive clinical and translational data. Additionally, the initiation of a Phase 1 solid tumor study and the dosing of the first patient, with results expected in the second half of 2024, signal significant progress. TScan’s intent to augment its ImmunoBank with new TCR-Ts, and the prospective initiation of a registration trial, keep investor interest piqued. These developments, along with the company’s strategy to expand its patient pool through the ImmunoBank, underscore Fein’s Buy rating and $15 price target for TScan Therapeutics.

According to TipRanks, Fein is a 5-star analyst with an average return of 12.0% and a 48.78% success rate. Fein covers the Healthcare sector, focusing on stocks such as Amylyx Pharmaceuticals Inc, Blueprint Medicines, and Foghorn Therapeutics.

In another report released today, Barclays also maintained a Buy rating on the stock with a $14.00 price target.

TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.

TScan Therapeutics (TCRX) Company Description:

TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company’s lead liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.